CION Ameerpet
If you or someone you love has a glioma, "will it progress?" is often the biggest worry. This guide explains how gliomas change over time, why molecular markers matter more than grade alone, and how a specialist team acts early.
Written by Dr. Kirti Ranjan Mohanty — Radiation Oncologist, CION Cancer Clinics, Hyderabad.
Medically reviewed by Dr. T. Raghavender Reddy — Medical Oncologist, CION Cancer Clinics, Hyderabad.
Last medically reviewed: June 2026
A glioma is a brain tumour that starts in the glial support cells of the brain. When doctors say a glioma is progressing, they mean it is growing on scans, changing in character, or causing new symptoms after a stable period. Progression is not a single event — it is a trend seen over time.
For a low-grade glioma, progression can be slow and quiet: a slightly larger area on MRI over many months, sometimes with no new symptoms at all. For a higher-grade glioma, the pace can be faster. This is exactly why gliomas are monitored with regular imaging rather than a single check.
One thing to understand early: not every change on a scan is true progression. After radiation, harmless inflammation — called pseudoprogression — can make an MRI look worse than the tumour actually is. Distinguishing the two takes an experienced neuro-oncology eye and, often, more than one scan.
The behaviour of a glioma is predicted more by its molecular markers than by its grade alone. Under the 2021 WHO classification of central nervous system tumours, gliomas are defined by markers such as IDH mutation and 1p/19q co-deletion — not just how the cells look under a microscope. Two tumours that look identical can behave very differently depending on their molecular profile. (Source: WHO Classification of Tumours of the CNS, 5th edition, 2021; NCCN Central Nervous System Cancers Guidelines.)
"Glioma getting worse" usually means one of two things. Knowing which one is happening matters, because it changes what the team recommends next.
The tumour is enlarging or spreading further into surrounding brain tissue, but its underlying grade may stay the same. On MRI this shows as a bigger tumour or a faster growth rate than before. Growth alone can be enough to prompt a change in treatment — even without a change in grade.
A low-grade glioma transformation means the tumour cells themselves become more aggressive — a Grade 2 tumour starts behaving like a Grade 3 or Grade 4 glioma. New contrast enhancement or necrosis on MRI can be a warning sign. Confirming transformation sometimes needs a repeat biopsy so treatment matches the tumour's current biology.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether your glioma is stable, growing, or you fear it has transformed, CION's neuro-oncology tumour board can review your imaging and markers and explain your options clearly.
Detecting glioma progression is about watching the trend, not reacting to a single image. CION provides brain MRI and diagnostic imaging directly, and every follow-up scan is compared against your earlier ones.
An MRI of the brain with gadolinium contrast is the primary way progression is picked up. Radiologists look for a tumour that is growing faster than before, a new area that "lights up" with contrast (new enhancement), or new areas of dead tissue (necrosis). Any of these can signal that a low-grade glioma is transforming into a higher grade.
Because inflammation after radiation (pseudoprogression) can mimic true growth, advanced MRI sequences — perfusion imaging and spectroscopy — help tell them apart by measuring blood flow and chemical activity within the tumour. This protects you from unnecessary changes to a treatment plan that is actually working.
If imaging strongly suggests transformation, a repeat tissue sample may be needed to confirm the new grade. A stereotactic biopsy is coordinated with accredited neurosurgical partners, and the sample is sent for both standard analysis and molecular re-testing so the next treatment is matched precisely to the tumour's current biology.
Grade tells you how the cells look today. Molecular markers tell you how the tumour is likely to behave over time — including how fast it may progress and how likely a low-grade glioma is to transform. CION arranges molecular testing as standard on glioma samples.
If your glioma was diagnosed without these tests, that is one of the most valuable reasons to seek a second opinion. Knowing your markers reshapes both the monitoring schedule and the treatment options.
The European Association of Neuro-Oncology (EANO) and NCCN both recommend molecular characterisation of every diffuse glioma at diagnosis, because IDH and 1p/19q status change how the tumour is classified, monitored, and treated — often more than the microscope grade does. (Source: EANO guidelines on diagnosis and treatment of diffuse gliomas; NCCN Central Nervous System Cancers Guidelines.)
There is no single speed. An IDH-mutant Grade 2 glioma may stay stable for years, while a Grade 4 glioblastoma can change over weeks to months. That range is exactly why molecular testing and regular scans matter so much — the timeline is driven by biology, not by a stopwatch.
Between routine scans, certain new, persistent, and progressive symptoms may suggest a glioma is progressing and should prompt a prompt call to your team rather than waiting:
These symptoms do not automatically mean transformation — but with a known glioma, they are a reason to be reviewed promptly. Speak to a CION neuro-oncologist or call 18002028726.
When a glioma progresses or transforms, the plan is re-reviewed by a multidisciplinary tumour board before anything changes. There is no single "next step" — it depends on the new grade, the tumour's location, what treatments you have already had, and your overall health. CION delivers the medical and radiation parts of this care directly, and coordinates surgery with accredited partners.
Progression after earlier treatment is closely related to recurrence — you can read more in our guide on whether a brain tumour can come back after removal, or explore the full picture of brain tumour treatment in Hyderabad.
For gliomas, a second opinion is most valuable in a few specific situations:
CION offers a dedicated free written second opinion. Start with the brain cancer & tumour hub for the wider picture, or book a consultation to have your own scans and reports reviewed.
Get a free written second opinion from CION's neuro-oncology team — especially valuable if your latest scan looks different or your molecular markers were never tested.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Progression means the glioma is growing, changing on scans, or causing new symptoms after a stable period. For a low-grade glioma, this can be slow — a slightly larger area on MRI over months or years. For a high-grade glioma it can be faster. Doctors look at the MRI, your symptoms, and sometimes a repeat biopsy before confirming true progression. Not every scan change is progression — after radiation, inflammation (called pseudoprogression) can mimic growth on MRI. That is why an experienced neuro-oncology team reviews the pattern over time, not a single image, before changing your plan.
Yes. Over time, many low-grade (WHO Grade 2) gliomas can undergo malignant transformation — the tumour cells become more aggressive and the tumour behaves like a Grade 3 or Grade 4 glioma. The risk and speed of transformation depend heavily on the tumour's molecular markers, especially IDH mutation and 1p/19q status. IDH-mutant gliomas generally transform more slowly than IDH wild-type tumours. This is why regular MRI monitoring matters — catching a change early gives you the most treatment options, from repeat surgery to radiation and systemic therapy.
Radiologists watch for specific changes on a follow-up MRI: a tumour that is growing faster than before, a new area that "lights up" with contrast (new enhancement), or new areas of dead tissue (necrosis). Advanced MRI sequences — perfusion imaging and spectroscopy — help tell true progression from treatment-related changes. A single suspicious scan is rarely enough on its own; the team compares it against your earlier scans to see the trend. In some cases, a repeat biopsy confirms the new grade so treatment can be matched precisely to the current biology of the tumour.
It varies enormously by tumour type. An IDH-mutant Grade 2 glioma may stay stable for years, while a Grade 4 glioblastoma can change over weeks to months. There is no single speed for "glioma getting worse" — that is exactly why molecular testing matters so much. Warning signs that a glioma may be progressing include new or worsening seizures, new weakness or numbness, changes in speech or vision, or headaches that are new and persistent. If you notice any of these, contact your neuro-oncology team promptly rather than waiting for your next routine scan.
When a glioma progresses or transforms, the plan is re-reviewed by a multidisciplinary tumour board. Options can include further surgery (coordinated with accredited neurosurgical partners), radiation therapy such as IMRT/IGRT delivered directly by CION, and systemic therapy chosen by drug class rather than a fixed recipe. Molecular re-testing may guide the next step. The right choice depends on the new grade, tumour location, your previous treatments, and your overall health. You can read more about recurrence in our guide on whether a brain tumour can come back after removal.
Yes. CION delivers directly the medical (systemic) therapy, radiation therapy (IMRT/IGRT), imaging and diagnosis, molecular testing, and steroid and seizure management that progressing gliomas need. Any neurosurgery — such as re-resection or a stereotactic biopsy to confirm transformation — is coordinated with accredited neurosurgical partners. Every case is reviewed by a tumour board, and you get a 45-minute consultation to understand your options. If you are worried about a changing scan or new symptoms, book a free consultation or explore brain tumour treatment in Hyderabad.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.